Foundation-funded Study Supports Hypothesis That Davunetide Prevents Cortical Thinning in Brains of Schizophrenia Patients

Jeffrey Lieberman, M.D.
Jeffrey Lieberman, MD

Foundation Scientific Council Member Jeffrey Lieberman, M.D. leads team in recent study using magnetic resonance imaging (MRI) data to measure the thickness of the cortex in specific regions of the brain in schizophrenia patients.

Dr. Lieberman explained that schizophrenia is a progressive neurodegenerative disease in which cortical thinning is believed to be responsible for some of the clinical symptoms and that this new finding supports the hypothesis that davunetide can prevent brain atrophy. 

Read more